CoChat

Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use

Open access
Brett, Jonathan, Knock, Elizabeth, Watson, Kathy, Albert, Steven, Siefried, Krista J., Guss, Jeffrey · 2024 · Frontiers in Psychiatry

The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index; 6 of the 7 sources its claims cite were checked for support.

Abstract

Methamphetamine (MA) dependence leads to severe physical and psychological issues. Current treatments, including psychosocial therapies and residential rehabilitation, face limitations such as high relapse rates, cost, and accessibility issues. As a result, there is an urgent need for novel approaches to treat MA dependence that are effective, affordable, and accessible to patients. Psilocybin, the active component in numerous mushrooms of the Psilocybe genus, has shown potential for enhancing psychotherapy for various addiction and mental health issues due to its effects on perception, cognition, and affect. Psilocybin-assisted psychotherapy (PAT) has demonstrated initial safety and efficacy in treating alcohol, cocaine, and nicotine dependence. The case presented here describes a 36-year-old transwoman and daily MA user, who participated in a single-arm open-label clinical trial assessing feasibility and safety of PAT for MA dependence at St. Vincent’s Hospital, Sydney. Following inpatient withdrawal management and one session of psilocybin-assisted therapy, she experienced significant cognitive and emotional shifts and sustained MA abstinence. She reported improved mental health over 3 months following treatment completion. She also noted increased self-esteem, mindfulness, and distress tolerance. This study suggests that PAT (following inpatient MA withdrawal management) may offer a scalable, safe, and effective approach for treating MA dependence. However, further research is required to confirm the generalisability and efficacy of PAT for broader populations of people using MA. It is encouraging that this participant, a daily MA user, showed improvements in mood and cognition, in addition to abstinence from MA. Copyright © 2024 Brett, Knock, Watson, Albert, Siefried and Guss.

Overview

CoChat Summary

TL;DR

This paper is a single case report from an open-label safety/feasibility study of psilocybin-assisted psychotherapy (PAT) for methamphetamine dependence. A 36-year-old transwoman who used methamphetamine daily reportedly achieved abstinence after inpatient withdrawal management plus one 25 mg oral psilocybin session, with improved mood, cognition, and self-reported coping over 3 months.

Key findings

  • The participant used methamphetamine on 27 of the prior 28 days at screening and had progressed to daily use, smoking 0.1 g to 0.5 g per session over the prior year.
  • After treatment, she reported complete abstinence from methamphetamine through 3 months, verified by drug urinalysis.
  • Craving scores on a 0–100 visual analogue scale fell from 100 at baseline to 28 at day 28 and 41 at day 90.
  • Her DASS-21 score improved from 13/21 at baseline to 6/21 at day 28 and 7/21 at day 90; quality of life on the WEMBS was 54/70 at baseline, 57/70 at day 28, and 50/70 at day 90.

Methods

  • Single case from a single-arm, open-label safety and feasibility study conducted in an outpatient setting at St. Vincent’s Hospital, Sydney, with follow-up to 3 months.
  • Intervention: 3 preparatory psychotherapy sessions over 2 weeks, inpatient withdrawal management for 5 days, then 25 mg oral psilocybin, followed by 2 integration psychotherapy sessions and return to usual care.
  • Outcomes assessed included safety/tolerability, methamphetamine use, craving, depression/anxiety/stress (DASS-21), quality of life (WEMBS), and two qualitative interviews.

Limitations

  • The paper explicitly states this is a single case report from a larger study, so its findings cannot establish efficacy or generalizability; it says “more research is required” and that larger randomized controlled studies are needed.
  • The text makes evident that the case had no control group and included multiple components (withdrawal management, psychotherapy, psilocybin), so the specific contribution of psilocybin cannot be isolated.
  • The participant later admitted to “microdosing” with small amounts of mushrooms on fewer than five occasions about 3 months later, which the text makes evident could complicate interpretation of longer-term outcomes.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fpsyt.2024.1490907

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

6 Valid · 1 Not valid · 1 Not checked · 21 Own results and interpretations

9 more claims

Create a free account to see all 29 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 10
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 2

  1. MacLean, 2017, Critical considerations in responding to crystal methamphetamine use in Australian Aboriginal communities, Drug Alcohol Rev, 36, 10.1111/dar.2017.36.issue-4 · doi:10.1111/dar.2017.36.issue-4
  2. Osman, 2012, The depression anxiety stress Scales—21 (DASS-21): further examination of dimensions, scale reliability, and correlates, J Clin Psychol, 68, 10.1002/jclp.2012.68.issue-12 · doi:10.1002/jclp.2012.68.issue-12

Cited by

See all 8

Metadata

Authors
Brett, J., Knock, E., Watson, K., Albert, S., Siefried, K. J., & Guss, J.
Affiliations
  • UNSW Sydney (AU)
  • St Vincent's Hospital Sydney (AU)
  • New York University (US)
Corresponding author
Brett, Jonathan
Venue
Frontiers in Psychiatry
Published
2024-12-06
Volume
15
Pages
1490907-1490907
ISSN
1664-0640 (ISSN-L)
OpenAlex
W4405122998
Cited by
7
References
25
Citations by year
2026: 2 · 2025: 5
FWCI
3.49
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by)
Funders
  • St. Vincent's Clinic Foundation
  • Usona Institute
  • Medical Research Council
  • National Health and Medical Research Council (1196900, 1196560)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Keywords
psilocybin-assisted therapy, methamphetamine dependence, abstinence, transgender women, feasibility and safety, mindfulness, distress tolerance, self-esteem, mood improvement, cognitive change

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.